Rodos BioTarget Receives Growth Financing of EUR 2.6 m

Rodos BioTarget GmbH (RBT) is pleased to announce that it has in 2012 successfully realized corporate investment actions in the amount of EUR 2.6 million, with additional option payments attached to its milestones for 2013. Institutional investors participating in this round include the InvestImpuls-Fonds of the region of Hannover (Germany) under the management of EnjoyVenture, the High-Tech Gründerfonds and the KfW’s ERP Start Fund. In addition to institutional investors, RBT was able to attract private domestic capital (family office and business angels), which is an as an encouraging signal for the German biotech industry as a whole.

Current growth investment funds are employed to finance all measures required to enter into clinical trials for establishing the TargoSphere® for the targeted delivery of active agents and vaccines into antigen-presenting cells.

RBT already achieved a crucial further milestone in its development by producing its proprietary platform nanotechnology, TargoSphere®, in an industrially upscaled and GMP-compliant process.

About Rodos BioTarget (RBT)
Certain bacterial and viral pathogens, as well as cancer cells, dramatically subvert the human immune defense cascade, resulting in devastating human, social, and economic conditions. In these diseases, various immune cells that are normally required to control and coordinate our human defenses are incapacitated. As a consequence, neither the pathogens nor the tumor can be controlled or eliminated, and even with state-of-the-art drugs, chronic disease or death is inevitable. RBT has invented and patented a unique platform technology targeted to the immune system that offers hope for effective remedies in various diseases. RBT’s TargoSphere® nanocarriers effectively deliver potent active compounds and vaccines directly into antigen-presenting cells of the immune system, resulting in site-specific therapeutic or protective actions. The TargoSphere® platform offers a unique and significant benefit for partners in the pharmaceutical industry. Novel therapeutic interventions can now be developed against infectious diseases and cancers, as well as against autoimmune diseases. Importantly, as a result of site-specific delivery, the TargoSphere® also permits for revised applications of already approved active agents, enabling an increase in efficacy at significantly lowered dosaging, thereby decreasing potential side effects and toxicities. Based on TargoSphere®, RBT currently develops an antiviral therapy (TargoVir) against Hepatitis C and HIV/AIDS, as well as an antibacterial approach (TargoBiotics) for newly developed applications, including pulmonary infections.
For additional information, please visit

Rodos BioTarget GmbH
Dr. M. Furch (CEO)
+ 49 (0)176 3921 3096

Dr. R. Gieseler-von der Crone (CSO)
+49 (0)176 6292 9350

About High-Tech Gruenderfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 573.5 million under management in two funds (EUR 272 million HTGF I, EUR 301.5 million HTGF II).

High-Tech Gründerfonds Management GmbH
Dr. Caroline Fichtner
Senior Investment Manager
Schlegelstraße 2
53113 Bonn
Tel.: + 49 228 823001-00


Notify of
Inline Feedbacks
View all comments